Related Experiment Video
Updated: Mar 12, 2026
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
A scoping review of symptom clusters during chemotherapy in colorectal cancer patients
He Mingqian1,2, Ji Yue1, Fang Juan1
1School of Medicine (School of Nursing), Huzhou University, 759 Erhuan East Road, Huzhou, 313000, Zhejiang, China.
Aim:
This scoping review synthesizes research on symptom clusters in colorectal cancer patients undergoing chemotherapy, identifying their types, assessment tools, and changes over time. The findings aim to guide future research and improve symptom management.
Methods:
Following the Joanna Briggs Institute's scoping review framework, a systematic search was conducted in PubMed, Embase, EBSCO (MEDLINE), Web of Science, Cochrane Library, CNKI, Wanfang, and VIP databases. The search period ranges from 2001 to December 25, 2024. Eligible studies underwent data extraction and synthesis.
Results:
Nineteen studies met the inclusion criteria. A total of 34 symptom clusters were identified, categorized into psychological, gastrointestinal, neurotoxic, and other clusters. Eight assessment tools were used, with the MD Anderson Symptom Inventory being the most common. Longitudinal studies revealed significant variations in symptom clusters throughout chemotherapy, emphasizing the need for continuous monitoring and intervention.
Conclusion:
The MD Anderson Symptom Inventory is widely used; however, consistent frameworks for naming and classifying the derived clusters are needed. A clearer understanding of symptom cluster dynamics is essential to inform targeted clinical interventions. Future research should focus on developing standardized classification approaches and examining the stability of symptom clusters over time to support improved symptom management.
Related Concept Videos
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...